Variables | No AF (n = 63) | AF (n = 16) | P value |
---|---|---|---|
Age (years) | 65 [59–70] | 73 [65–76] | 0.026 |
BMI (kg.m−2) | 31.5 [24.9–40.7] | 29.3 [26.2–32.8] | 0.8 |
SAPS II score during TTE | 32 [21–49] | 58 [43–62] | 0.001 |
Male gender (n; %) | 40 (65) | 14 (88) | 0.12 |
Medical history | |||
No history | 8 (13) | 3 (19) | 0.68 |
Hypertension | 31 (50) | 12 (75) | 0.09 |
Diabetes | 13 (21) | 6 (38) | 0.19 |
Dyslipidemia | 19 (31) | 4 (25) | 0.76 |
Smoking (former or active) | 20 (33) | 4 (25) | 0.76 |
Chronic renal disease | 5 (8) | 2 (12) | 0.62 |
COPD/asthma | 11 (18) | 2 (13) | 1 |
Coronary or peripheral artery disease | 15 (24) | 5 (32) | 0.53 |
Obstructive sleep apnea | 5 (8) | 1 (6) | 1 |
Chronic treatment | |||
Statine | 19 (31) | 7 (44) | 0.38 |
Beta blocker | 17 (28) | 6 (38) | 0.54 |
ACE inhibitor | 11 (18) | 5 (32) | 0.30 |
ARBs | 14 (23) | 3 (18) | 1 |
Diuretic | 9 (15) | 4 (25) | 0.45 |
Aspirin | 14 (23) | 6 (38) | 0.33 |
Metformin | 9 (15) | 4 (25) | 0.45 |
Time to first symptom to ICU admission (days) | 8 [5–11] | 8 [4–14] | 0.56 |
COVID 19 specific treatment (n = 67/89) | |||
Dexamethasone | 49 (81) | 11 (74) | 0.70 |
Remdesevir | 3 (5) | 0 | 1 |
Tocillizumab | 1 (2) | 0 | 1 |
Atrial fibrillation | |||
Previous paroxysmal AF | 6 (10) | 2 (12) | 0.61 |
Occurrence of AF, (days) | – | 7 [2–11] | – |
CHA2DS2-VASc | 2 [1–3] | 3 [1–4] | 0.20 |
Outcome | |||
Arterial thromboembolic events | 0 | 1 (6)* | 0.21 |
Length under MV, days | 17 [10–24] | 28 [16–44] | < 0.001 |
Mortality at 30-days | 14 (22) | 7 (43) | 0.11 |
ICU discharge, days | 61 (93) | 13 (82) | 0.06 |
Length of stay in ICU, days | 12 [5–21] | 25 [14–33] | < 0.001 |